Boehringer Ingelheim unveils new $11.8 billion strategy in R&D
German family-owned drug major Boehringer Ingelheim has detailed a new research and development strategy and says it will focus on pursuing outside collaborations.
The company plans to invest 11 billion euros ($11.8 billion) over the next five years as part of a new research and development strategy. Of that, 5 billion euros will go to preclinical research through 2020, and 1.5 billion euros will go to collaborations with external partners.
Andreas Barner, chairman of the company, said: "This is another decisive step to position Boehringer Ingelheim for long-term growth... we are looking forward to addressing unresolved challenges in immunology, respiratory and cardiometabolic medicine, as well as in oncology, in diseases of the central nervous system and beyond."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze